{"id":"NCT01355458","sponsor":"Galderma R&D","briefTitle":"Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea","officialTitle":"A Multicenter, Randomized Double-Blind, Vehicle-Controlled, Parallel Group Study to Demonstrate the Efficacy and Safety of CD07805/47 Gel Applied Topically Once Daily in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-05","primaryCompletion":"2011-09","completion":"2011-12","firstPosted":"2011-05-18","resultsPosted":"2013-11-21","lastUpdate":"2021-02-18"},"enrollment":260,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Rosacea"],"interventions":[{"type":"DRUG","name":"CD07805/47 gel","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"CD07805/47 gel","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Phase 3 efficacy and safety study of CD07805/47 topical gel in subjects with facial erythema associated with rosacea. The study hypothesis is that CD07805/47 gel, applied topically once daily is more efficacious than vehicle and provides an acceptable safety profile in the treatment of facial erythema associated with rosacea.","primaryOutcome":{"measure":"Composite Success","timeFrame":"Day 29","effectByArm":[{"arm":"CD07805/47 Gel","deltaMin":40,"sd":null},{"arm":"Placebo","deltaMin":14,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":15,"countries":["United States","Canada"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":129},"commonTop":[]}}